Our Directors

Combining many years of business acumen, first hand IP experience and expertise, they form the core of the Biofusion team.

  • Doug Liversidge, Chairman

    Appointed to the Board of Biofusion plc on 1 December 2004, having been a director of Biofusion Trading since 28 November 2003. He was employed for 21 years at British Steel, before moving to G W Thornton Limited as Managing Director and subsequently Chief Executive. He guided the company through its flotation on the full list of the London Stock Exchange in March 1987. In 1991 Mr. Liversidge was awarded South Yorkshire Businessman of the Year.

    Mr. Liversidge acts as a Senior Industrial Advisor to the University of Sheffieldand was awarded the CBE in the 2000 New Year's Honours List for services to industry.

  • David Baynes, CEO

    Appointed to the Board of Biofusion plc on 2 November 2004, having been a director of Biofusion Trading since 2 January 2003. David has previously worked at Celsis International plc ("Celsis") from its incorporation to its flotation on the full list of the London Stock Exchange in July 1993;  Toad plc (now TG21 plc), which he co-founded, and was responsible for taking the company from start-up to a full listing on the London Stock Exchange; Whereonearth Limited; Codemasters Limited.

  • Dr Peter Grant, Operations Director

    Appointed to the Board of Biofusion plc on 1 December 2004, having been a director of Biofusion Trading since 2 January 2003. Peter has a PhD in Biochemistry from Cardiff University and has previously worked at Genzyme UK Limited; Celltech Limited; Enzymatix Limited and Celsis plc, which he co-founded and took to a full listing on the London Stock Exchange.

  • Stuart Gall, Commercial Director

    Appointed to the Board of Biofusion plc on 27 April 2005. Mr. Gall has experience in both small company start-ups and public companies and specialises in marketing, communications and new business development. He has previously worked at British Airways plc, The Promotions Partnership Limited, Anvil Limited and Toad plc (now TG21 plc).

  • Dr. Edwin Moses, non-executive director

    Appointed to the Board of Biofusion plc on 1 December 2004. Dr. Moses has extensive experience as a non-executive director for companies including Evotec OAI AG, BioImage A/S, Inpharmatica Ltd, Ionix Limited, Amedis Limited, Avantium Technologies BV, Paradigm Therapeutics and Clinphone Limited.

  • Professor Tony Atkinson

    Appointed to the Board of Biofusion plc on 1 December 2004, Prof. Atkinson has extensive experience as both a director and non-executive director for companies including Generic Biologicals, Kymed, Enact Pharma and Chimereran.

  • David Catton, non-executive director

    Mr. Catton was appointed to the Board of Biofusion plc on 1 December 2004, having been a director of Biofusion Trading since 14 August 2003. David is Managing Director of SUEL, the University of Sheffield’s tech transfer operation. Prior to this David worked for Ford Motor Company, British Leyland (now Rover), Rank Xerox Limited and Cambridge Consultants Limited.

  • Mike Davies, Non executive director

    Appointed to the Board of Biofusion on 5 February 2007, Mike is Cardiff University’s Director of Physical and Financial Resources. Mike has gained extensive experience of Cardiff’s technology transfer activities through his role as Chairman of UC3, and as a Director/Company Secretary of the General Partner Board of the Cardiff Partnership Fund.

  • Simon Oakland, Non executive director

    Appointed to the Board of Biofusion on 19 April 2006. Simon is a Principal of Nikko Principal Investments Limited (“NPIL”), the European principal finance arm of Nikko Cordial Corporation, and a Director of NPI Ventures. Simon previously worked for the Corporate Finance Department of Cazenove & Co. and prior to that was a management consultant at Accenture.

  • Richard Birtles, Company Secretary

    Mr. Birtles has been a University employee for 20 years and is company secretary to seven companies.

    Prior to joining SUEL in 2001, Richard was Head of Special Projects at the University and a member of the successful City of Sheffield Team which secured the HQ of the United Kingdom Sports Institute for Sheffield, in particular being responsible for developing the corporate structure and financial planning for the Institute involving a joint venture arrangement between private funders and the National Lottery with a capital budget in excess of £100 million.